For research use only. Not for therapeutic Use.
BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils.
BF-227 has a high binding affinity for Aβ1-42 fibrils. The Ki value for Aβ1-42 fibrils in competitive binding assay using [125I]BF-180 is 4.3±1.3 nM in BF-227 (Kd value of [125I]BF-180: 10.8±1.5 nM)[1]. [11C]BF-227 is a PET tracer. The AUC for BF-227 (0.994) is much higher than that for FDG (0.839), indicating that BF-227 is more sensitive as well as more specific than FDG in diagnosing AD[2].
Catalog Number | I019835 |
CAS Number | 845647-80-5 |
Synonyms | 5-[(E)-2-[6-(2-fluoroethoxy)-1,3-benzoxazol-2-yl]ethenyl]-N,N-dimethyl-1,3-thiazol-2-amine |
Molecular Formula | C16H16FN3O2S |
Purity | ≥95% |
InChI | InChI=1S/C16H16FN3O2S/c1-20(2)16-18-10-12(23-16)4-6-15-19-13-5-3-11(21-8-7-17)9-14(13)22-15/h3-6,9-10H,7-8H2,1-2H3/b6-4+ |
InChIKey | GSZMUPHKOPBPPS-GQCTYLIASA-N |
SMILES | CN(C)C1=NC=C(S1)C=CC2=NC3=C(O2)C=C(C=C3)OCCF |
Reference | [1]. Kudo Y, et al. Development of amyloid imaging PET probes for an early diagnosis of Alzheimer’s disease. Minim Invasive Ther Allied Technol. 2006;15(4):209-13. [2]. Furukawa K, et al. Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG-PET. J Neurol. 2010 May;257(5):721-7. |